Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-… Read more
Stoke Therapeutics Inc (STOK) - Net Assets
Latest net assets as of September 2025: $308.11 Million USD
Based on the latest financial reports, Stoke Therapeutics Inc (STOK) has net assets worth $308.11 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($360.26 Million) and total liabilities ($52.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $308.11 Million |
| % of Total Assets | 85.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | -19.94% |
| 10-Year Change | N/A |
| Growth Volatility | 47.68 |
Stoke Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how Stoke Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Stoke Therapeutics Inc (2017–2024)
The table below shows the annual net assets of Stoke Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $229.02 Million | +43.53% |
| 2023-12-31 | $159.56 Million | -13.68% |
| 2022-12-31 | $184.85 Million | -15.12% |
| 2021-12-31 | $217.78 Million | -23.87% |
| 2020-12-31 | $286.08 Million | +27.47% |
| 2019-12-31 | $224.43 Million | +113.60% |
| 2018-12-31 | $105.07 Million | +8232.20% |
| 2017-12-31 | $-1.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Stoke Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 47764100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $-151.00K | -0.07% |
| Other Components | $720.00 Million | 314.38% |
| Total Equity | $229.02 Million | 100.00% |
Stoke Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Stoke Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ivanhoe Electric Inc.
NYSE MKT:IE
|
$1.39 Billion |
|
Lakeland Financial Corporation
NASDAQ:LKFN
|
$1.39 Billion |
|
Uniti Group Inc
NASDAQ:UNIT
|
$1.39 Billion |
|
Jonjee Hi-tech Industrial and Commercial Holding Co Ltd
SHG:600872
|
$1.39 Billion |
|
Befesa S.A
PINK:BFSAF
|
$1.39 Billion |
|
NCC AB ser. B
LSE:0OFP
|
$1.39 Billion |
|
Kontron AG
VI:KTN
|
$1.39 Billion |
|
CMB.TECH NV
NYSE:CMBT
|
$1.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Stoke Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 159,565,000 to 229,021,000, a change of 69,456,000 (43.5%).
- Net loss of 88,981,000 reduced equity.
- New share issuances of 128,840,000 increased equity.
- Other comprehensive income decreased equity by 127,000.
- Other factors increased equity by 29,724,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-88.98 Million | -38.85% |
| Share Issuances | $128.84 Million | +56.26% |
| Other Comprehensive Income | $-127.00K | -0.06% |
| Other Changes | $29.72 Million | +12.98% |
| Total Change | $- | 43.53% |
Book Value vs Market Value Analysis
This analysis compares Stoke Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.05 | $33.96 | x |
| 2018-12-31 | $4.47 | $33.96 | x |
| 2019-12-31 | $12.49 | $33.96 | x |
| 2020-12-31 | $8.54 | $33.96 | x |
| 2021-12-31 | $5.93 | $33.96 | x |
| 2022-12-31 | $4.75 | $33.96 | x |
| 2023-12-31 | $3.63 | $33.96 | x |
| 2024-12-31 | $4.24 | $33.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Stoke Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -38.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -243.42%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.19x
- Recent ROE (-38.85%) is below the historical average (-29.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.43 Million |
| 2018 | -11.92% | 0.00% | 0.00x | 1.02x | $-23.03 Million |
| 2019 | -12.71% | 0.00% | 0.00x | 1.02x | $-50.97 Million |
| 2020 | -17.69% | 0.00% | 0.00x | 1.04x | $-79.22 Million |
| 2021 | -38.90% | -2823.70% | 0.01x | 1.10x | $-106.49 Million |
| 2022 | -50.37% | -750.58% | 0.05x | 1.39x | $-111.59 Million |
| 2023 | -65.62% | -1192.47% | 0.04x | 1.43x | $-120.66 Million |
| 2024 | -38.85% | -243.42% | 0.13x | 1.19x | $-111.88 Million |
Industry Comparison
This section compares Stoke Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Stoke Therapeutics Inc (STOK) | $308.11 Million | 0.00% | 0.17x | $1.39 Billion |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |